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Tuberculosis is still to this day the most widespread infectious disease globally. The spread of 
drug-resistant strains which has been reported to be attributed to primary transmission 
threatens TB control and prevention programmes. Previous molecular epidemiological 
studies have reported that the dynamics of tuberculosis transmission varies geographically.  
The aim of the present study was to describe the drug-resistant tuberculosis epidemic and 
identify transmission hotspots and possible outbreaks of drug-resistant tuberculosis within the 
West Coast region of the Western Cape, South Africa. We used the internationally 
standardised spoligotyping method to classify Mycobacterium tuberculosis into different 
lineages and strain family and DNA sequencing of drug resistance conferring genes to 
genotypically characterise drug-resistant tuberculosis isolates collected from the West Coast 
region over a 5 year period (2008-2012).  
Spoligotyping data revealed the X-family as the most dominant M. tuberculosis strain family, 
followed by the Beijing family. Our findings are contradicting to what has been reported in 
the rest of the Western Cape Province that identified the Beijing family to be the predominant 
family responsible for drug-resistant tuberculosis within the province.  
We identified a cluster of multidrug-resistant isolates mainly located in the Northern parts of 
the region, harbouring similar spoligotyping patterns and identical mutations conferring 
resistance to the 4 first-line drugs used in tuberculosis treatment. This is indicative of 
transmission. Isolates belonging to this outbreak, but with different additional mutations 
conferring to resistance to second-line drugs were also identified, indicating that Pre-XDR 
and XDR-TB are primarily acquired on an existing MDR strain genotype.  
Even though spoligotyping is considered to have a low discriminatory power and could 
overestimate the extent of transmission, this study described an epidemic spread of multi-
drug resistant strains in the West Coast region of the Western Cape. Our study highlighted the 
regional variation of outbreaks and the need for molecular epidemiology studies in various 
regions to tailor interventions to curb TB and drug-resistant TB spread.  
 





Tuberkulose (TB) is steeds die mees wydverspreide aansteeklike siekte wêreldwyd. TB 
beheer en voorkomingsprogramme word bedreig deur middel-weerstandige TB wat ook 
wêreldwyd aangemeld word en meestal toegeskryf word aan primêre oordrag van die siekte 
tussen pasiënte. Vorige molekulêre epidemiologiese studies het gewys dat die dinamika van 
tuberkulose oordrag verskillend is in verskillende geografiese areas.  
Die doel van hierdie studie was om die middel-weerstandige tuberkulose epidemie in die 
Weskus distrik van die Wes-Kaap, Suid-Afrika te beskryf, en om potensiële uitbrake van 
middelweerstandige tuberkulose te identifiseer. Ons het gebruik gemaak van die 
internasionaal gestandaardiseerde spoligotipering metode om Mycobacterium tuberculosis in 
verskillende stamme en families te klassifiseer en DNA volgorde bepaling om mutasies wat 
middelweerstand veroorsaak te indentifiseer. Die studie is gedoen op isolate van TB pasiënte 
van die Weskus streek oor 'n tydperk van 5 jaar (2008-2012). 
Spoligotipering het gewys dat die X-familie as die mees dominante M. tuberculosis 
stamfamilie is, gevolg deur die Beijing stamfamilie. Ons bevindinge is teenstrydig teen wat 
voorheen giving is in the res van die Wes-Kaap Province, data die Beijing family 
oorheersend is en meestal verantwoordelik is vir middelweerstandige tuberkulose in die 
provinsie. 
Ons het verder 'n groep van multi-weerstandige isolate geïdentifiseer in die noordelike dele 
van die streek, met soortgelyke spoligotipering patrone en identiese mutasies wat 
weerstandigheid teen die 4 eerste linie middels veroorsaak. Dit is 'n aanduiding van oordrag 
van 'n multi-weerstandige stam familie in die streek. Isolate wat deel is van hierdie uitbraak, 
maar met verskillende bykomende mutasies wat weerstandigheid teen tweede linie middels 
het is ook geïdentifiseer, en dui daarop dat Ekstreem Weerstandige TB ontwikkel het deur 
mutasies wat later ontwikkel. 
Selfs al word spoligotipering beskou as 'n tegniek met minder diskriminerende waarde as 
ander ginotiperings tegnieke, en daarom die mate van tuberculose oordragf kan oorskat,  
bewys hierdie studie dat 'n multi-middelweerstandige epidemie versprei in die Weskus van 
die Wes-Kaap. Ons studie beklemtoon die noodsaaklikheid vir molekulêre epidemiologie 
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1.1 Introduction  
 
Tuberculosis (TB) caused by Mycobacterium tuberculosis is still to this day the most 
widespread infectious disease globally (1, 2). In addition, the World Health Organisation 
(WHO) reported an estimated 1.1 million people co-infected with human immunodeficiency 
virus (HIV) and TB worldwide (3). Furthermore, more than 50% of the TB cases co-infected 
with HIV were recorded in Sub-Saharan Africa (3). This global problem is further 
complicated by the emergence and rise of drug-resistant (DR) TB, most of which is believed 
to be attributed to primary transmission (4).  
 
An estimated 480 000 cases of multidrug-resistant (MDR) TB, defined as (resistance to at 
least isoniazid (INH) and rifampicin (RIF), the two key first-line drugs) were recorded in 
2014 worldwide, threatening TB control programs (5). Moreover, the widespread emergence 
of extensively drug-resistant (XDR) TB (defined as MDR-TB with additional bacillary 
resistance to any of the fluoroquinolones and at least one of the three second-line injectable 
drugs: kanamycin [KAN], amikacin [AMK] or capreomycin [CAP]) cases is alarming (6). 
Several studies have reported that most cases of  MDR-TB and XDR-TB in South Africa and 
globally result from primary transmission (4, 7–11). Continued transmission is not only 
exhibited in inadequately treated patients with no known drug resistance, but also in 
undetected, undiagnosed patients which predisposes communities to outbreaks (12–14).  
 
South Africa has been reported to have high and increasing rates of DR-TB. Studies have 
documented that the drug resistance burden in the Western Cape province is due to ongoing 
transmission (15, 16). Furthermore, previous studies suggests that the W/Beijing M. 
tuberculosis  strain family drives the TB epidemic, in particular DR-TB in the Western Cape 
Province (17–19). Molecular epidemiological tools used in combination with traditional 
investigation techniques have improved and broadened our understanding of TB 
epidemiology by providing insight into the transmission dynamics of M. tuberculosis (20–
22). Application of geospatial mapping of case clusters and whole genome sequencing 
(WGS) coupled with social network analysis (SNA) have provided a guideline to aid in 
public health responses (23–25).  




Although genotypic and phenotypic characterisation of DR-TB strains has been done in the 
Western Cape Province (7, 16, 26), very little has been reported in the West Coast district of 
this Province (27). Furthermore, this region has an alarmingly high estimated TB incidence of 
1224.9/100 000 population (28). Molecular epidemiology studies have demonstrated that the 
dynamics of TB transmission vary geographically (29). A study by Hanekom et al. suggested 
that some strains disseminate and cause disease more efficiently than others (30), it is 
therefore vital to understand the dynamics governing DR-TB transmission in this region. 
 
We hypothesise that a sudden increase in DR-TB cases in an area is indicative of recent 
transmission and a possible outbreak of a DR strain of tuberculosis. Therefore, the aim of the 
current study was to describe the DR-TB epidemic in the West Coast district of the Western 
Cape Province and to identify possible transmission hotspots. To achieve this aim, we have 3 
specific objectives: 1) to describe the DR-TB strain population by spoligotyping, and thereby 
identify possible clusters of drug resistance; 2) to identify mutations associated with drug 
resistance of the most prominent strain families by polymerase chain reaction (PCR) 
amplification and Sanger sequencing; and 3) to identify and map out transmission hotspots of 
DR-TB. 
 
Chapter 2 is an overview of the literature relevant to the study; it describes the molecular 
epidemiology tools used in outbreak investigations and their limitations and also reports on 
studies of DR-TB outbreaks in different settings and the lessons learned. Chapter 3 is a brief 
description of material and methods used in the study, buffers and solutions are included in 
the appendices. The results from data generated in the study are in Chapter 4, this includes 
the distribution of strain families in the area, mutations conferring drug resistance in the 
prominent strain family and areas were transmission is evident. In chapter 5 we discuss the 













































Tuberculosis remains an enormous public health burden globally (1). The WHO reported an 
estimated 9.6 million new cases of TB and 1.5 million deaths from TB, including about 1.1 
million deaths among individuals who were HIV negative and among 0.4 million people who 
were HIV positive in 2014 (2). These reports emerge despite available antituberculous 
therapy that could cure most cases of TB (3).  
 
2.1.1 Drug resistance 
 
Acquired drug resistance emerges as a result of spontaneous selection of mutations in certain 
chromosomal genes during suboptimal therapy (4–6) whereas primary resistance develops 
when an individual is infected with a resistant strain (7). The emergence and increase in 
MDR-TB seriously threaten TB prevention programmes. Moreover, global reports of XDR-
TB in 105 countries have emerged stressing the need for current control measures to be 
augmented (2). These forms of TB do not respond to the standard six-month regimen with 
first-line anti-TB drugs and can take up to two or more years to treat with drugs that are less 
effective and much more expensive (8). In 2009, Velayati et al. identified a strain of TB that 
showed in-vitro resistance to all first- and second-line drugs tested. The term “totally drug-
resistant tuberculosis (TDR-TB)” was proposed for this strain (9). These dangerous forms of 
TB bacilli which have not been clearly defined have subsequently been reported in other 
countries (Italy, India and South Africa) (10–12). Failure to reinforce control and prevention 
of TB may result in outbreaks that are difficult and expensive to control. 
 
2.2 Drug-resistant TB outbreaks 
2.2.1 Definition of an outbreak 
The WHO defines an outbreak of any sort as the unusual increase of disease in a defined 
community or geographical area (13). An outbreak may be confined to a geographical area, 
or spread over several countries. It may be short-lived or long-lived (13). A study by Marais 
et al. identified a large number of MDR-TB strains and multiple clusters circulating within 
the greater Johannesburg area of South Africa which could be considered as disease in excess 




and fits the description of an outbreak. However, transmission in this study was attributed to 
numerous source cases and described as an epidemic spread and not an isolated clonal 
outbreak (14). Owing to the alarming outbreak reports and absence of a tailored definition of 
an outbreak of DR-TB, the present review is undertaken to describe global outbreaks of DR-
TB and how the application of molecular epidemiology tools coupled with traditional 
epidemiological investigations aided in the control of outbreaks. 
Outbreaks of DR-TB have been reported worldwide in communities and institutions (15). 
Prior to the era of molecular techniques, understanding the dissemination of TB relied on 
observational data (16). Detection of a cluster of M. tuberculosis resistant profiles was 
indicative of an outbreak; this was achieved through case history, contact investigation, 
tuberculin skin test and drug susceptibility tests (DST). Advances in molecular microbiology, 
that enable differentiation of strains of M. tuberculosis by use of deoxyribonucleic acid 
(DNA) fingerprinting have provided new insights into tuberculosis epidemiology (17). 
Isolates with identical fingerprints are termed a cluster and are indicative of recent 
transmission while isolates with unique fingerprints are considered unrelated (18).    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
2.3 Molecular epidemiological tools used to identify and confirm outbreaks 
2.3.1 IS6110  
 
Different techniques have been standardised and used in molecular epidemiology studies 
(19). IS6110-restriction fragment length polymorphism (RFLP) is the first standardised 
fingerprinting technique for TB epidemiology (20). This technique is based on the presence 
of the insertion sequence in different positions of the M. tuberculosis genome. M. 
tuberculosis complex has been reported to contain 0-25 copies of IS6110. Considered to be a 
gold standard until recently (21), IS6110 typing is the most widely used method for 
molecular epidemiological studies because of the high degree of discriminatory power 
achieved with this method (22). However, this technique has its own flaws (23) as it is 
laborious and needs relatively large amounts of DNA. Furthermore, it requires prior culture 
and produces results that are not easy to compare across laboratories (24).  
 
2.3.2 Polymorphic guanine-cytosine-rich sequence-RFLP 





Polymorphic guanine-cytosine-rich sequence (PGRS) makes use of the, polymorphic 
guanine-cytosine (GC)-rich sequence contained in the recombinant plasmid pTBN12 as a 
probe (25, 26). The poor discriminatory power of IS6110-RFLP when applied to low copy 
number strains has been resolved by use of PGRS, which has high discriminatory power 
when applied to low copy strains. Although highly discriminatory, the process is lengthy and 
the results are difficult to interpret.  
 
2.3.3 Polymerase Chain Reaction based typing 
 
2.3.3.1 Spoligotyping  
 
Spoligotyping is based on PCR amplification of the highly polymorphic direct repeat locus 
which is a member of the clustered regularly interspaced short palindromic repeats 
(CRISPRs) using membrane format or Luminex® technology (Luminex Corp., Austin, TX) 
(27). Spoligotyping is less discriminatory than IS6110 typing when high copy number strains 
are being analysed but it is superior for the evaluation of low copy number strains (22). It is 
not complicated, rapid and robust, but low in discriminatory power (22). 
 
2.3.3.2 Mycobacterial interspersed repetitive unit-variable number tandem repeats 
 
Mycobacterial interspersed repetitive unit-variable number tandem repeats (MIRU-VNTR) 
typing is based on polymorphisms of the MIRU loci. MIRUs are short (40-100 base pairs) 
DNA elements, often found as tandem repeats and spread in intergenic regions in the genome 
of the M. tuberculosis complex (28). MIRU-VNTR is a portable, reproducible and 
discriminatory tool and has been adopted as an international standard (21, 28, 29). It 
produced more distinct patterns when compared with IS6110-RFLP and spoligotyping (30, 
31). However, this technique is time consuming. 
 
2.3.4 Drug resistance associated mutations 
 




Drug resistance associated mutations have lately been used coupled with other molecular 
epidemiological techniques to define clustering of M. tuberculosis isolates (32, 33). Drug 
resistance mutations are determined by PCR amplification followed by sequencing of the 
target region or hybridization of the target amplicon with immobilized probes representative 
of a possible mutation causing drug resistance (34, 35). This approach is limited to isolates 
with drug resistance.  
 
2.3.5 Whole genome sequencing  
 
Whole genome sequencing (WGS) is based on analysis of whole genome sequence data 
generated by next-generation sequencing. The discriminatory power of analysing the whole 
genome makes it superior to all other genotyping methods, with the additional benefit that a 
complete drug resistance profile based on drug resistance causing mutations could be 
compiled. Unfortunately, this will not be feasible to identify outbreaks of TB or DR-TB in 
“real-time” in areas with a high burden of tuberculosis, since the cost of sequencing is still 
too high and the technique and analysis is time consuming (20).  
 
2.3.6 The use of geographical information system in outbreak investigations 
 
The use of geographical information system (GIS) coupled with molecular epidemiological 
tools can be a dual force in outbreak investigations, enabling identification of clusters and 
localising transmission. Although rarely used in resource limited settings, GIS has 
successfully been utilized in a study to localise an outbreak (36). However, the application of 
GIS is only effective in areas where streets and houses are properly numbered and mapped, 
which is not the case for low-income settings. In such instances, global position system 












2.4 Global reports of outbreaks of DR-TB 
 
2.4.1 Nosocomial outbreaks 
 
Drug-resistant TB outbreaks within health care facilities have been reported in various 
geographical settings. This could possibly be resulting from an active spread of TB bacilli by 
undiagnosed and inadequately treated patients where poor prevention and infection control 
measures are in place. This was evident in an outbreak of a highly resistant strain that was 
reported in New York City (37), where more than two thirds of the patients were reported to 
have been infected with the strain designated as the “W-strain” in the nosocomial setting 
(37). A high HIV co-infection was also documented among patients. Genotyping was done 
using IS6110-RFLP which has a high discriminatory power in identifying identical or closely 
related cases. Poor infection control and inadequate treatment contributed to transmission. 
Ripples of nosocomial TB transmission were also documented in hospitals across the United 
States of America (USA), which stressed for effective prevention and control efforts to be 
augmented (38–40). The surge of nosocomial outbreaks was reported to be attributed to 
neglect and decline in public health efforts (41). Reinforcement of infection control, 
preventive measures and improvements in directly observed treatment short course (DOTs) 
resulted in a decline in transmission (42). 
The lesson from the above mentioned outbreaks (37) has been poorly implemented by TB 
control programs, especially in resource limited settings such as sub-Saharan Africa, South 
Africa in particular, which has been reported to have a high prevalence in cases co-infected 
with HIV (43). The suboptimal treatment regimens of patients with susceptible TB and poor 
infection control has both allowed for selection of DR forms of TB and transmission. Lack of 
effective prevention and control measures cascaded into the highly publicised hospital 
transmission of XDR-TB in Tugela Ferry, a rural town in the South African province of 
KwaZulu-Natal (KZN). HIV co-infection was documented in all patients that were tested. 
Furthermore, all but one of the patients died within a fortnight of diagnosis. Genotypic 
analysis was enhanced by using both IS6110-RFLP and spoligotyping, which enabled 
identification of the patients that were in the same cluster and strain family which was 
subsequently named F15/LAM4/KZN strain (44). The high fatality among patients diagnosed 




with XDR-TB and apparent transmissions in the hospital setting led to a major international 
rethink of treatment strategies. The finding in this study suggests that HIV positive patients 
are at high risk of acquiring resistant forms of TB. This is consistent with reports by other 
studies that documented rapid progression to TB infection in patients who were HIV positive 
(45, 46) and stresses for improved isolation of HIV infected patients from patients diagnosed 
with TB. In addition, prompt antiretroviral treatment should be administered for effective 
management of TB infection. These studies show that hospital settings can facilitate the 
transmission of tuberculosis if infection control measures are not in place. In addition, not 
only are patients at risk, health care workers (HCW) also contribute to the spread of TB in the 
health care facilities (47, 48). These findings have important implications for TB infection 
control. It has been reported that implementing effective infection control measures in health 
care facilities can reduce the risk of tuberculosis transmission (49). The WHO recommends 
that some set of guidelines at administrative, environmental and personal level be 
implemented. Administrative control measures include prompt identification of patients 
infected with TB, isolation of infected patients, administration of proper treatment, reduced 
hospital stays, improvement in lab testing and notification to prevent diagnostic delays and 
support of health care workers by implementing routine screening and HIV testing (49). This 
works effectively in conjunction with implementation of effective environmental control 
measures that involve reduction and control of infectious air by both mechanical and natural 
ventilation. However, implementation and maintenance of mechanical ventilation in low 
resource settings could be costly. Such settings rely on natural ventilation which has been 
reported to be effective provided that air is directed to the outside and not within the corridors 
(50). Use of ultraviolet germicidal irradiation (UVGI) has also been recommended as an 
infection control measure to limit transmission, especially in cold settings (51). However, the 
effectiveness of UVGI depends on the vertical air movement between the upper and the lower 
room and is only effective in areas with low relative humidity (52). Although it has been 
reported to reduce rates of transmission (51), further upgrades are necessary to improve 
safety and efficacy, more importantly in high risk regions. Furthermore, the WHO 
recommends particulate respirators for HCW who are attending to patients to prevent 
transmission of TB (49, 53). Nosocomial outbreaks have also been reported in Italy, England, 
USA, South Africa, Argentina and Spain (54–60), see table 1. 
2.4.2 Community and household outbreaks 




TB transmission is not only isolated to health care facilities but extends to households and 
community settings. Studies have reported that contacts exposed to patients with active TB 
are vulnerable to infection by primary transmission, especially in settings reported to have a 
high burden of HIV (61, 62). 
2.4.2.1 Household outbreaks 
Exposure of close contacts to index cases prior to diagnosis puts them at risk for TB 
transmission (61, 63). This was seen in a study that reported an outbreak of MDR-TB and 
tuberculous meningitis in a single family (64). All patients were reported to be 
immunocompetent. Genotyping by PCR based on amplification of IS6110 revealed a closely 
related pattern. In addition, isolates from two of the patients harbored the rpoB mutation and 
had the same RFLP profile, suggesting an intra-familial transmission. Mortality of two of the 
patients was attributed to neurological complications. The study highlighted the importance 
of early detection, adequate treatment and adequate isolation measures. This outbreak could 
have been prevented if prompt and correct diagnosis was done. This report is consistent with 
a study that reported household settings as one of the transmission hotspots (65). A study by 
Vella et al. (66) stressed the importance of an early and strong contact tracing to limit 
transmission which could in turn reduce TB in high incidence areas (67, 68). It has been 
recommended that a contact investigation be initiated after detection of an infectious case. 
(69). However, this may be difficult to implement in resource limited settings (70).  
2.4.2.2 Community outbreaks 
Transmission is not only exhibited in households but frequently occurs in communities were 
social mixing is heightened. This could result from exposure of contacts to active cases in 
social areas. A community outbreak was reported among non-institutionalised and HIV 
seronegative patients in Cape Town, South Africa (71). Genotyping by IS6110-RFLP and use 
of dot blot hybridization of mutations conferring drug resistance to four first-line drugs 
enabled identification of a cluster of 16 MDR-TB patients. The strain was indiscriminately 
referred to as the “U strain” which is “strain W-like”. Isolates from the initial MDR-TB 
episode exhibited mutations in the katG315, katG463, rpoB531, rrs513 and embB306 
conferring resistance to INH, RIF, streptomycin (STR) and ethambutol (EMB) respectively. 
The study redefined what was known as a norm in a high incidence area. This study also 




emphasised on the importance of prompt and correct diagnosis with administration of optimal 
treatment (71). Studies have further documented that the youth, progressing to adolescence 
and young adults are vulnerable to exposure of TB from infectious cases during social 
contact, particularly in an enclosed setting with minimal ventilation (65, 72). It has also been 
shown that contacts are at risk of transmission of highly resistant strains from active 
undetected cases who were infected in health care facilities (73). In addition, undetected 
miners who migrate to and from the mines in low resource and high prevalence regions such 
as sub-Saharan Africa serve as a potential threat to households and communities (74). 
These studies gave insight into transmission dynamics in households and communities and 
stressed the need for intensive case detection and contact investigation, regardless of regional 
HIV and drug resistance prevalence (75). Adhering to the lessons learnt from these outbreaks 
will enable identification of undetected or undiagnosed cases and initiation of treatment to 
control the spread of TB (70, 76). Furthermore, incorporating recent genotyping tools such as 
WGS, could enhance findings that could not be achieved by classic epidemiological tools and 
genotyping alone, owing to the higher discriminatory power that WGS exhibits (77). 
2.4.3 Outbreaks in prisons 
Incarcerated persons are at risk of transmission of tuberculosis due to overcrowding and poor 
ventilation (78, 79). In addition, risk factors such as substance abuse and HIV infection 
contribute to high rates of tuberculosis in prisons. Furthermore, lack of screening 
programmes for early identification of TB allow for ongoing transmission from undetected 
infectious persons (79, 80). This was highlighted in a study by Valway et al (81). A contact 
investigation was initiated following the death of four inmates attributed to MDR-TB 
infection. Investigation identified nine cases with MDR-TB and 96 (30%) contacts with a 
positive skin test. All cases had the same drug resistance patterns. Identical patterns were 
obtained using IS6110-RFLP, confirming a true outbreak. Furthermore, all outbreak cases 
were immunocompromised, nine were HIV positive and one was diagnosed with cancer. This 
is consistent with a study by McLaughlin et al. that showed that transmission is elevated in 
settings where HIV infected persons are congregated (82). Transmission was attributed to an 
undiagnosed source case with active MDR-TB (81). The study highlights the importance of 
intensive screening programs and effective infection control measures. It has also been 




documented that infected inmates also pose as a threat to community contacts after they are 
released (79, 83).  
Early identification of cases infected with TB and initiation of appropriate treatment is 
mandatory in preventing transmission. This should be done in conjunction with improvement 
of infection control practices. The WHO recommends that managerial activities involving 
policy makers be implemented to ensure effective planning and implementation of infection 
control (49). Furthermore, administrative controls that include screening of newly infected 
and long term inmates, educating and encouraging staff to seek medical attention when they 
present with symptoms as well as screening for HIV and counselling must be instituted (49, 
79). In addition, all case reports of suspected and confirmed TB cases must be reported to 
health departments. This will ensure that adequate resources are available for case 
management and contact investigations in and out of the correctional facility and enable 
follow up of released inmates who are infected with TB (79, 84). The Centres for Disease 
Control and Prevention (CDC) (Atlanta, Georgia, USA) also recommends that environmental 
control measures be instituted such as local exhaust ventilation and UVGI which has been 
reported to have limitations as mentioned above in health care infection control measures 
(52). Moreover, adequate personal respiratory protection is recommended for use when 
entering isolated rooms with infected patients and during transportation of infectious inmates 
(79). Further reports of community and household outbreaks have been reported in Benin, 
Taiwan, Argentina, Norway, Austria, Singapore and Virginia (36, 85–90), see table 1. 
2.4.4 Outbreaks in schools 
The long hours of contact among students and educators in enclosed spaces favour 
transmission, which makes schools potential outbreak settings. One such outbreak was 
reported in California and occurred from 1991-1993. A retrospective cohort study was 
initiated following  diagnosis of four high school students with TB resistant to three first-line 
drugs (91). A total of 18 active cases were identified. Eight culture positive isolates that were 
available for IS6110-RFLP typing exhibited identical patterns. The index case was 
documented to have been infectious for a prolonged period of time resulting in transmission. 
Furthermore, risk of infection was found to be high among contacts of an infectious student. 
Subsequent screening detected additional cases of positive reactors. The study demonstrated 
the discriminatory power of IS6110-RFLP in comparison to conventional phenotypic 




techniques and the importance of continuous screening in schools to prevent transmission. In 
addition, patients receiving treatment should be monitored using effective DOTs to ensure 
treatment adherence. Prevention measures such as educating students about TB transmission 
and when to seek medical attention should also be instituted. Furthermore, infection control 
measures should be implemented; this may include adequate ventilation in classrooms and 
sitting areas. School outbreaks of DR-TB have also been reported in Ireland, Spain and South 
Africa, which is a high incidence area (91–93), see table 1.   
2.4.5 Outbreaks among foreign born persons 
Transmission among foreign born, homeless persons and illicit drug users continue to 
challenge TB control efforts in developed countries. Immigrants who migrate from areas with 
high prevalence to areas with low incidence of TB pose a threat to communities leading to an 
increase in rates of transmission (94). From 2005-2006 a cluster of four MDR-TB cases were 
identified in Austria with matching genotypes confirmed by MIRU-VNTR typing (24 loci). 
All four cases were HIV seronegative and refugees. Non-adherence, ineffective follow up and 
inappropriate treatment of the highly infectious index case led to transmission. Combination 
of MIRU-VNTR typing with high discriminatory power and spoligotyping as an initial 
screening tool was conclusive in confirming this study as an outbreak. The findings were  
consistent with reports from a meta-analysis that documented that refugees were four times 
more likely to be diagnosed with active pulmonary TB than other immigrants (95). Another 
study reported an outbreak of MDR-TB among US-bound Hmong refugees in Thailand (96). 
Of the screened refugees, a total of 272 patients were diagnosed with TB. Genotyping was 
done by MIRU, Spoligotyping and IS6110-RFLP. Twenty of the 23 MDR-TB patients had 
matching genotypes by the 3 molecular techniques. The other 3 exhibited unique patterns. 
The study defined an outbreak based on three criteria: social links, matching genotypes by 
three molecular techniques and increase in tuberculin reactivity among smear positive 
household contacts. The study underscored the importance of prompt diagnosis of active 
cases and initiation of treatment to prevent transmission and importation of virulent strains to 
different geographical locations. Moreover, the study also highlighted the effectiveness of 
utilizing genotypic techniques in conjunction with classic epidemiology to get to the root of 
transmission. Screening on entry into developed countries has been a main countermeasure, 
especially for migrants coming from countries with high prevalence of TB (94). Moreover, 




subsequent screening to oversee the trends in specific populations is highly recommended 
(94). However, a study stressed that although screening of refugees is easy since they are 
under surveillance, it may be difficult for migrants owing to the various entry points that they 
may use (97). Furthermore, Menzies et al. stressed that screening upon entry and 
administration of treatment alone is not effective in reducing the TB incidence from the 
country of origin, since immigrants reactivate as soon as they enter the developed countries 
with low TB incidence. Hence a global coordinated effort is required to avert TB 
transmission (98). Another outbreak has also been reported in Norway (87), see table 2.1.  
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An understanding of how outbreaks emerge and the molecular epidemiological tools used to 
confirm transmission can help in controlling the spread of DR-TB strains. We reviewed 
outbreak reports of DR-TB in different settings.  
Reports suggested that the most vulnerable cases were the immunocompromised and those 
that were in congregated environments, such as schools, prisons and hospitals. Findings from 
the above studies clearly indicated that transmission was the driving force for the DR-TB 
outbreaks and was fuelled by inadequately treated and undetected cases. Furthermore, poor 
infection control contributed to the dissemination of the DR strains. 
Lack of knowledge also contributed to the spread of DR-TB as the general public are in most 
cases ill-informed about the symptoms of the disease and thereby, patients with TB did not 
seek medical attention when they presented with symptoms and only did when the disease 
had progressed, infecting a number of contacts before they were diagnosed. This could have 
also resulted from fear of the stigma associated with diseases such as HIV, especially in 
resource limited settings. Follow up of cases was highlighted, which stressed for routine 
follow up of patients undergoing treatment and those that were found to be latently infected 
with TB. The studies also emphasised on promptly reporting to TB control.   
 
There is a deficit in prevention and control measures; clearly what is in place is not effective 
enough to combat this scourge. An explanation could be poor management of the 
recommended programs. The resurgence of TB in New York City bears as evidence of what 
neglect or poor TB management could lead to. Hence, there is a need for control efforts to be 
instituted in various institutions and settings to halt transmission (37). A rapid and effective 
approach is mandatory to tackle this situation. There is a need for prompt diagnosis of 
infected cases using rapid diagnostic tests such as The Genotype® MTBDRplus and 
MTBDRsl (Hain Life Science, Nehren, Germany) and GeneXpert™ MTB/RIF (Cepheid, 
Germany). In future, routine use of WGS could be implemented to aid in identification of 
drug resistance and identifying possible transmission chains. 
 
In order to prevent future DR-TB outbreaks globally, there is a need for continuous roll out of 
treatment, decentralised treatment should be tightened by having trained personnel and 




adequate resources. This will enable patients to achieve high cure rates. Failure to reinforce 
prevention and control programs could result in outbreaks of strains that do not respond to 
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3.1 Geographical location 
 
The West Coast is among the district municipalities of the Western Cape Province, it is 
bordered by the Atlantic Ocean on the west and the Northern Cape on the north and east. This 
area is characterised by a high TB prevalence of 1224.9/100 000 population (28). The five 
local municipalities within the West Coast are: Matsikama, Swartland, Bergrivier, Cederberg 
and Saldanha Bay.  
 
3.2 Sample selection 
 
A longitudinal reference database and corresponding sample bank house in the Division of 
Molecular Biology and Human Genetics were available for this study. All viable DR-TB 
isolates diagnosed at the reference laboratory of the National Health Laboratory Service 
(NHLS) from the Western Cape Province were collected and stored since 2007, with 
phenotypic drug susceptibility testing (DST) results and basic demographic data of the 
patients. Ethical clearance was obtained from the Ethics Committee (reference number 
N09/11/296). All isolates from patients who originated from the West Coast district, collected 
from 2008-2012 were extracted from the database (n=786). One isolate from each patient was 
selected for analysis. If a patient had more than 1 isolate in the sample bank, the first isolate 
with resistance to the most drugs was selected (n=611).   
 




To describe the DR-TB strain population in the West Coast region we made use of 
spoligotyping. This genotyping technique makes use of the DR region present in the genome 
of members of the M. tuberculosis complex (31). The DR region is made up of direct repeats 
(DRs), interspersed with unique DNA sequences, termed spacers (see figure 3.1). 
Spoligotyping is a reverse line probe assay, where the primers in the PCR step are based on 
the repeat sequences, thereby amplifying the unique sequences in between the DRs, labelled 







with Biotin for downstream visualization with Streptavidin and Enhanced 
Immunohistochemistry (ECL). The PCR products are then hybridised to a membrane 
containing 43 probes compliment to spacer sequences derived from the laboratory strain 
H37Rv and the vaccine strain M. bovis bacilli Calmette-Guérin (BCG) (32).  Evolution of the 
DR region can be via homologous recombination, single nucleotide polymorphisms, or 
disruptions by the insertion element, IS6110 (33). After hybridization of the DNA on the 
membrane, the presence or absence of the spacer DNA is visualized by enhanced ECL on an 
X-Ray. The presence of the spacer DNA is indicated by a black block, and the absence of a 
block indicates the absence of the spacer DNA. Thereby generating a characteristic pattern 
for each strain analysed. 
Figure 3.1 The principle of PCR amplification of the DR region using primer “a” and primer 
“b” based on the DR region of the M. tuberculosis complex 
 
3.3.1.1 Spoligotyping Protocol 
Spoligotyping was performed using the internationally standardised method to identify strain 
families (34). For PCR amplification: the PCR master mix was made up as set out in table 
3.1 
Table 3.1 PCR master mix 
H20 6.5µl 
Kapa Taq ready mix 12.5µl 







DRb (supplied with manufacturer) 2µl 
DRa (biotinylated 5' end)  (supplied with 
manufacturer) 
2µl 
Template DNA 2µl 
 
M. bovis BCG and H37Rv DNA were included as positive controls. The PCR mixture was 
placed in the thermocycler and subjected to the following conditions: 3 minutes at 95°C 
followed by 30 cycles at 94°C for 1 minute, 55°C for 1 minute, 72°C for 30 seconds and 
72°C for 10 minutes. For hybridization, 20µl of PCR product was diluted by adding 160µl of 
2XSSPE/0.1%SDS and heat denatured for 10 minutes at 99°C and immediately cooled on 
ice. The membrane (Mapmygenome™, India) with covalently bound oligonucleotides was 
washed at 60°C in 2XSSPE for 10 minutes and placed on a support cushion in a miniblotter 
(Mapmygenome™, India) with slots perpendicular to 43 immobilised oligonucleotides. The 
residual fluid from the slots was removed by aspiration and denatured PCR products were 
pipetted into parallel slots with caution to avoid bubbles. Hybridization was done for 60 
minutes at 60°C on a horizontal surface. PCR products were removed from the miniblotter by 
aspiration. The membrane was washed twice for 5-10 minutes each time in 
2XSSPE/0.5%SDS at 60°C and then incubated in 40ml of 2XSSPE/0.5%SDS with 12.5µl 
streptavidin-peroxidase conjugate (500U/ml) (Roche, Germany) for 60 minutes at 42°C. 
Following incubation, the membrane was washed twice for 5-10 minutes each time in 
2XSSPE/0.5%SDS at 42°C and rinsed with 2xSSPE for 5 minutes at room temperature. The 
membrane was incubated in 20ml of (10 ml solution A and 10 ml solution B) of enhanced 
chemiluminescence ECL (Amersham ECL Direct
TM
 nucleic acid labelling and detection 
system, GE Healthcare Limited, Little Chalfont, UK) detection liquid for 1½ minutes. The X-
ray film was exposed to the membrane for 5-20 minutes in a dark room and developed using 
an automated developer. The membrane was stripped by washing twice in 1%SDS for 30 
minutes each time at 80°C and stored at 4°C in 20Mm EDTA (Sigma Aldrich) at pH 7.0 in a 
sealed plastic container for repeated use. 
 
3.3.2 Targeted gene sequencing  
 







Genes or gene regions, associated with drug resistance were PCR amplified and sequenced 
using Sanger sequencing to detect mutations conferring drug resistance.  
 
3.3.2.1 PCR amplification  
 
M. tuberculosis target genes (inhA promoter, katG, rpoB, embB, pncA, gyrA and rrs) were 
PCR amplified using designed primers, table 3.2.  
 
Table 3.2 Primers used for amplification of genes conferring resistance 
Drug resistance 
phenotype 
primer Sequence (5'to 3') Fragment 
length 
Tm 
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PCR reactions were made up to 25µl total volume, containing 6.375µl of H20, 5µl of Q 
solution, 2.5µl 10x buffer, 4µl MgCl2 (25 Mm), 4µl dNTPs (10mM), 1µl each of forward and 
reverse primer (50pmol/uL), 1µl Syto9 florescent dye (1:00 dilution) (Life technologies, 
Oregon, USA), 0.125 µl HotStar Taq polymerase (Qiagen, Hilden, Germany) and 2µl DNA 
that was grown on liquid culture and boiled for half an hour. Amplification conditions were 
as follows: 15 minutes at 95°C, followed by 40 cycles at 94°C for 1 min, Tm for 1 minute, 72 
°C for 1 minute and 72°C for 10 minutes (see table 3.2 for each specific Tm). The rpoB 
target gene was the exception, because of the high Tm of the primers, the reaction mixture 
was subjected to a touchdown PCR as follows: 15 minutes at 95°C, followed by 2 cycles at 
94°C for 1 minute, 72°C for 1 minute, 72°C for 1 minute, 2 cycles at 94°C for 1 minute, 71°C 
for 1 minute, 72°C for 1 minute, 2 cycles at 94°C for 1 minute, 70°C for 1 minute, 72°C for 1 
minute, 40 cycles at 94°C for 1 minute, 69°C for 1 minute, 72°C for 1 minute and 72°C for 
10 minutes. H37Rv laboratory strain was used as a positive control and water was included as 
a negative control. Successful PCR Amplification was confirmed using the Rotor gene 
V1.787 high resolution melt (HRM) analysis. The H37Rv laboratory strain DNA was used as 
a positive control and water as a negative control. The PCR products were subjected to a high 
resolution melt as follows: ramp from 80°C to 95°C rising by 0.1 °C each step, waiting for 90 
seconds of pre-melt conditions on the first step and for 2 seconds of each step afterwards.  As 
the temperature increases, the double stranded DNA becomes single stranded and releases the 
intercalated Syto9 fluorescence dye. The decrease in fluorescence is measured in real time as 
represented in an example plotted with Fluorescence (df) vs. temperature (dt) which 
generates a melting curve, see figure 3.2. The peaks differ in different genes owing to the 
DNA fragments. 
 







   
Figure 3.2 Example of a Melt curve of High resolution Melt to confirm successful PCR 
amplification of rpoB gene.   
 
3.3.2.2 DNA Sequencing 
 
PCR products were sequenced by Sanger sequencing at the Central Analytical Facility (CAF) 
at Stellenbosch University. Briefly, Post PCR clean-up of the PCR products was done using 
the Agencourt AMPure XP PCR Purification system (Agencourt Bioscience Corporation, 
Beckman Coulter, Beverly, Massachusetts) according to the manufacturer’s instructions. PCR 
products were sequenced using the forward amplification primer. The DNA sequencing 
reaction was done using a GeneAmp 9700 thermal cycler (Applied Biosystems, Foster City, 
CA 94404 USA). The following sequence program was selected; 5 minutes at 94°C, followed 
by 25 cycles at 94°C for 10 seconds, 55°C for 10 seconds and 60°C for 4 minutes. The 
sequencing reaction was cleaned using Centri-Sep™ columns (Princeton Separations Inc, 
Adelphia, NJ 07710 USA) and then electrophoresed on an ABI3730xl genetic analyser 
(Applied Biosystems, Foster City, CA 94404 USA) using the standard run module for the 
50cm capillary. Base calling was performed using Sequencing analysis V5.3.1 with the 







“mixed base setting” set at 10% allowing for the detection of minority single nucleotide 
polymorphisms. 
 
3.3.3 Sequencing analysis 
 
Gene sequences were aligned using Bio Edit version 7.1.3 and the respective gene sequence 
of M. tuberculosis H37Rv reference strain obtained from tuberculist. 
(http://genolist.pasteur.fr/TubercuList/) 
 
3.4 Phylogenetic analysis 
 
In order to identify possible outbreak clones of the X-family circulating in the West Coast 
region, a phylogeny was constructed with the isolates belonging to this family and all 
sequencing results from the 7 conferring genes were available. The spoligotype pattern, and 
each variable region sequenced were concatenated to produce a FASTA file for each isolate. 
The general time-reversal (GTR) model of substitution was applied to construct a maximum 
likelihood phylogeny of the isolates included in this analysis with Randomized Axelerated 


















































4.1 Demographic data  
 
We conducted a retrospective study of DR-TB isolates that were collected in the West Coast 
district of the Western Cape Province, South Africa, from 2008-2012. Patient drug-
susceptibility tests and demographic data were routinely collected from the five local 
municipalities within the West Coast district (see table 4.1). A total of 611 DR-TB patients 
were included in the study. Of these, 349 (57%) were male and 251 (40%) were female. Data 
was not available for 11 (1.8%) of the patients and were designated as unknown. The average 
age among the patients with confirmed DR-TB was 35 years. The HIV status and other 
clinical data were not available for this study.   
 
Table 4.1 The Distribution of patients in the West Coast District within the local 
municipalities and respective towns. 
Local Municipality   Town   
Matsikama 212 Vredendal 100 
  Lutzville 65 
  Klawer 33 
  van Rhynsdorp 6 
  Bitterfontein 5 
    Rietpoort 3 
Swartland 127 Malmesbury 77 
  Moorreesburg 33 
  Riebeeck 
Kasteel 
8 
  Riebeeck West 5 
  Darling 2 
    Melkbosstrand 2 
Cederberg 112 Clanwilliam 55 
  Citrusdal 30 
  Graafwater 15 
  Lamberts Bay 7 
    Elands Bay 5 
Saldanha Bay 100 Vredenburg 93 
  Hopefield 3 
  Langebaan 3 
    Saldanha 1 
Berg River 60 Porterville 32 
    Piketberg 28 







4.2 Phenotypic drug resistance  
 
Drug-susceptibility data for the isolates was routinely collected from the National Health 
Laboratory Service (NHLS) at Greenpoint, Western Cape Province. These tests were 
routinely done as requested by the clinicians. The INH/RIF mono-resistance was defined as 
resistance to either one of the first-line antituberculous drugs. Polyresistance was defined as 
resistance to more than one antituberculous drug but not MDR. MDR-TB was defined as 
resistance to at least INH and RIF. Pre-XDR-TB was defined as MDR-TB with added 
resistance to either the fluoroquinolone, ofloxacin (OFL) or injectable drug, (AMK). 
Extensively drug-resistant TB was defined as MDR-TB with resistance to both OFL and 
AMK. 
 
We identified a high proportion of patients diagnosed with MDR-TB (n=297; 49%). We also 
identified more INH monoresistant isolates (n=133; 22%) as compared to the isolates that 
were RIF monoresistant (n=81; 13%). Furthermore 60 (10%) patients had pre-XDR-TB and 
19 (3%) had XDR-TB. Five patients (1%) were classified as poly-resistant, while for 16 (3%) 
patients, we did not have adequate DST results and could not classify them, hence designated 
as unclassified.  
 
4.3 Genotyping  
 
To determine the distribution of DR-TB strain families in the West Coast district, the isolates 
from each case with the highest number of resistance phenotype were genotyped using 
spoligotyping. The strain families were classified according to the international SITVIT 
database (37). The spoligotypes that have not been assigned a spoligo international type (SIT) 
were referred to as orphans and numbered according to the local spoligotype (LT) and 
classified to belong to a specific spoligotype family and lineage according to distinct 
signatures. Spoligotype patterns that were not previously identified in SITVIT, were also 
assigned a LT, but not classified into an international family/clade. The spoligotyping 
signatures of M. tuberculosis that were identified in this region are shown in table 4.2. 
 







4.3.1 Spoligotyping analysis 
  
We identified 9 spoligotype lineages of M. tuberculosis within the region, these included: the 
Beijing family (n=154; 25%), X-family (n=246; 40%), T-family (n=63; 10%), S-family 
(n=45; 8%), Latin American Mediterranean (LAM) (n=44; 7%), Central Asia (CAS) (n=11; 
2%), Manu (n=8 ; 1%), Haarlem (n=8; 1%) and East African Indian (EAI) family (n=5; 1%), 
see figure 4.1. The predominant family identified was the X-family, followed by the Beijing 
family. Patients infected with M. tuberculosis X-family were male (54%) the average ages 
were 35 years. This is not statistically different to the total population or patients infected 
with the Beijing strain family of M. tuberculosis (61% male, average age 34). The breakdown 
of M. tuberculosis strain families within the lineages are shown in table 4.2. 
Figure 4.1.  Distribution of spoligotype lineages that were identified from the West Coast 
district.  








Table 4.2. Spoligotyping signatures of M. tuberculosis identified in the West Coast 
Lineage nr of 
isolates 
Int family‘ nr of isolates SIT
#
 Spoligotype pattern nr of isolates 
X 246 X1 192 119  186 






    
336  3 
    
302  2 
  
X3 36 92  35 
    
2286  1 
  
X2 18 137  17 
    
347  1 
Beijing 154 BEIJING 154 1  153 
    
190  1 
T 63 T1 48 53  17 
    
244  11 
    
1067  8 
    
136  4 
    
462  3 
    
628  1 
    
732  1 
    
913  1 
    
1202  1 
    
1737  1 
  
T1_RUS2 6 280  6 
  
T4_CEU1 3 39  3 
  





    
44  3 
  
T5_RUS1 2 254  2 
S 45 S 44 34  32 
    
789  9 






    
494  1 
    
1333  1 
  
U 1 790  1 
LAM 44 LAM3 29 33  17 
    
719  4 
    Orphan^ (LT
*
-43)  1 
    
2345  2 
    
1331  1 
    
1335  1 
    
2302  1 







    
4  2 
  
LAM1 6 20  6 
  
LAM11_ZWE 4 59  2 
    
2017  1 
    
2196  1 
  
LAM4 4 60  4 
  
LAM9 1 42  1 
CAS 11 CAS1_DELHI 10 26  9 
    
25  1 
  
CAS 1 357  1 
Manu 8 MANU2 8 54  2 
    
226  2 
    
2229  2 
    
1634  1 
    
2117  1 
Haarlem 8 H1 3 47  2 
    
62  1 
  
H3 3 50  3 
  
H4 1 921  1 
  
U (likely H) 1 46  1 
EAI 5 EAI1_SOM 4 48  3 
    
806  1 
  
EAI5 1 236  1 
unknown 27 
 
NOT IN SITVIT LT747  5 
    
LT974  1 
    
LT1017  1 
    
LT1013  1 
    
LT1028  1 
    
LT1030  1 
    
LT1160  1 
    
LT1139  1 
    
LT1157  1 
    
LT994  1 
    
LT1161  1 
    
LT1092  1 
    
2306  2 
    
519  1 
    
602  1 
    
1241  1 
    
no result  6 
Legend to Table 4.2 
*
LT-local type, ‘Int-international family, 
#
SIT- spoligo international type, ^Orphan- 
Present in the international database only once. 
 
 







4.3.2 Drug resistance and sequencing of drug resistance conferring genes of the X-
family 
 
Since the X-family was the predominant cause for DR-TB of the West Coast region, further 
analysis was focused on isolates from this lineage. Genes or gene regions associated with 
drug resistance were analysed by PCR amplification followed by DNA sequencing. 
 
4.3.3 Sequencing analysis (n=246) 
 
Of the isolates that were identified to belong to the X-family, we identified mutations at 
codon 315(AAC, ACA, ACC and AGA) of the katG gene and mutations in the inhA promoter 
region (-15C-T) conferring INH resistance. The rifampicin resistance determining region 
(RRDR) harboured mutations at codon 511(CCG), 516(TAC), 526(GAC and CTC), 531 
(TTG) and 533(CCG) of the rpoB gene conferring RIF resistance. Mutations conferring PZA 
resistance were identified throughout the pncA gene at position 105(GAC), 132(AGT), 139 
(ATG), 143(GTC), 154(GGG), 164(CCG), 180(GCC), 35(CGG), 62(CTG), 68(GGG) and 
85(CCG). We identified codons harbouring the embB mutation, codon 306(ATA, ATC, ATT, 
GTG) and codon 328(TAT) conferring EMB resistance. The gyrA gene conferring OFL 
resistance harboured mutations at codons, 89(GGC), 90(GTG), 91(CCG) and 94(AAC, GCC, 
GGC). Mutations conferring kanamycin resistance were identified at position 1401A-G, see 
table 4.3.  
 
Table 4.3 Different mutations identified in 7 drug resistance conferring genes 
 
Gene Mutation Nr of 
isolates 
rpoB CTG511CCG 17 
 GAC516GTC 2 
 GAC516TAC 1 
 CAC526CTC 28 
 CAC526GAC 1 
 TCG531TTG 184 
 CTG533CCG 1 







 Wild type 10 
 no result 2 
   
katG AGC315AAC 1 
 AGC315ACA 196 
 AGC315ACC 21 
 AGC315AGA 1 
 Wild type 22 
 no result 5 
   
inhA 
prom 
-15 C-T 7 
 Wild type 237 
 no result 2 
   
pncA GGC105GAC 1 
 GGT132AGT 3 
 GTG139ATG 134 
 GCC143GTC 3 
 AGG154GGG 1 
 TCG164CCG 1 
 GTC180GCC 4 
 CTG35CGG 1 
 CCG62CTG 1 
 TGG68GGG 1 
 CTG85CCG 1 
 Wild type 82 
 no result 13 
   
embB ATG306ATA 6 
 ATG306ATC 1 
 ATG306ATT 1 
 ATG306GTG 137 
 GAT328TAT 4 
 Wild type 83 
 no result 14 
   
gyrA GAC89GGC 1 
 GCG90GTG 14 
 TCG91CCG 7 
 GAC94AAC 1 







 GAC94GCC 7 
 GAC94GGC 29 
 Wild type 185 
 no result 2 
   
rrs 1401 A-G 12 
 1402 C-A 1 
 Wild type 224 
 no results 9 
 
DNA sequencing of drug resistance conferring genes and DST correlates as has been 
previously reported (38–41) with the best correlation between RIF and rpoB (38) and the 
lowest EMB and embB (39), Ethambutol susceptibility testing been known to be inaccurate 
and has been suspended by the routine lab during the course of the study (as indicate by the 
limited numbers in table 4.4.) 
 





Sensitivity Specificity correlation Nr of isolates 
RIF rpoB 99.1 66.7 97.5 242 
INH katG and 
inhA 
promoter 
96.4 68.8 94.6 239 
EMB embB 100.0 32.3 35.0 103 
OFL gyrA 67.4 86.7 82.7 226 
AMI rrs 1400 
region 
69.2 99.0 97.2 217 
 
4.4 Phylogeny of the X-family 
 
A combination of spoligotype patterns and the identified gene mutations associated with drug 
resistance were used to construct a maximum likelihood phylogenetic tree, in order to 
identify possible outbreak strains, see figure 4.2. For this, all isolates that had complete 
sequencing data of all 7 drug resistance conferring mutations were included (n=221). A large 
MDR cluster of 50 isolates were identified harbouring identical katG315ACA, rpoB531TTG, 
pncA139ATG and embB306GTG mutations. Furthermore, 53 isolates with additional 







mutations, leading to pre-XDR-and XDR-TB that form part of this outbreak were present on 











Figure 4.2 Maximum likelihood phylogenetic tree selected clinical isolates of M. 
tuberculosis. A maximum likelihood phylogeny was constructed using model parameters 
GTR+G and 1000 bootstraps with the RAxML phylogenetic software based on selected drug 
resistance associated regions of M. tuberculosis. The municipalities are symbolised by letters, 
Matsikama (M), Cederberg (C), Swartland (SL), Bergrivier (B) and Saldanha bay (SB). 







4.5 Geographical distribution of an outbreak.  
 
Based on the results obtained from the phylogenetic tree, we selected all isolates that 
harboured the same katG315ACA, rpoB531TTG, pncA139ATG and embB306GTG 
mutations and plotted them on a map of where they originated and classification of drug 
resistance based on mutations identified. The patients were clustered mainly in and around 3 
major towns: Vredendal, Lutzville and Clanwilliam. These towns are located in the Northern 




















Figure 4.3 Geographical distribution of patients infected with an outbreak strain of M. 














































 DR-TB continues to be a major problem globally, even though prevention and control 
measures have been recommended (3). The emergence and spread of DR-TB has been 
attributed to inadequate treatment, delay in diagnosis of drug resistance and infection control 
measures. In the current study, we aimed to describe the DR-TB epidemic in the West Coast 
region of the Western Cape Province. Very limited data has been reported on molecular 
epidemiology in this region as compared to the rest of the Western Cape. Furthermore, a very 
high prevalence (1224.9/100 000 population) of TB has been reported which is alarming.  
 
Analysis of DST by the routine laboratory showed that INH mono-resistant strains were more 
represented than RIF mono-resistant strains. This could be because RIF was not yet selected 
or that phenotypic DST could not pick up low level RIF resistance (42). Another possible 
explanation could be because INH resistance occurs more frequently than RIF resistance, 
since multiple genes and gene regions could be the reason to confer INH resistance compared 
to RIF, which only the RRDR are involved in drug resistance (43). We observed a low 
specificity for detecting RIF resistance by genotyping. This is skewed by the limited number 
of RIF sensitive strains that was present in the cohort tested. Furthermore, 3 of the 4 isolates 
that was resistant to RIF, had a rpoB526CTC mutation that is associated with low level RIF 
resistance (1ug/ml) (M. Whitfield, unpublished data), that could give false positive DST 
results.   
 
Using spoligotyping as a molecular tool coupled with sequencing of M. tuberculosis target 
genes which confer resistance, we showed that there was an epidemic spread of DR-TB 
strains. The dominant strain families identified were the X-family, Beijing family, T-family, 
S-family and LAM. This is similar to other previously reported studies in the Western Cape 
Province that reported primary transmission as the major contributor of the circulating DR 
strains (16, 26). The X-family was identified as the predominant family in this region which 
is contrary to other studies that have reported the Beijing strain as the dominating strain in the 
Western Cape (7, 18). Furthermore, large outbreaks have been attributed to the Beijing 
lineage (44), suggesting that the Beijing strain is able to spread more efficiently as compared 
to other genotypes (45, 46).  








The X-family has also been identified as one of the predominant M. tuberculosis strain 
families in the Western Cape (47). Other strains that were identified in this study included the 
Beijing, LAM and T families (47). Our group also previously reported a clone of the X-
family which is characterized by deletion of spacer 18 and spacers 33-36 with the same 
katG315ACA mutation (26). The X-family strain has also been reported to be highly 
prevalent in the United States and the United Kingdom (48).  
 
Phylogeny based on spoligotyping and drug resistance conferring mutations suggested high 
similarities of MDR strains, and more variations on a pre-XDR and XDR-TB level. This is 
indicative that MDR-TB is mainly due to transmission, and subsequently pre-XDR and XDR-
TB are due to acquisition of additional mutations. These strains either have not had time to 
spread or could have an additional fitness cost, making them less able to spread as 
successfully as the susceptible or MDR counterparts. 
 
We also identified various clusters of identical genotypes in the X-family, including a large 
cluster of the X-family with 4 identical first-line drug resistance markers in (rpoB, katG, 
pncA and embB). Sub-branches of this cluster indicate subsequent mutations leading to pre-
XDR- and XDR-TB. These strains were mainly found in 2 of the Northern most 
municipalities of the region. This provides evidence of an outbreak of DR-TB in this region 
that contributes to the TB overall epidemic in the region.  
 
To overcome the delay of diagnosing drug resistance in tuberculosis, a rapid, point-of-care 
DR diagnostics, GeneXpert has been introduced on a large scale in South Africa, including in 
this region. This will hopefully aid in identifying DR-TB more rapidly, in order to slow down 
transmission and possible outbreaks of DR-TB. 
 
Possible interesting future studies would be to determine if rapid diagnostics of DR-TB 
would have slowed down this epidemic, by doing this kind of study over a different time 
period. It would also be interesting to incorporate WGS of the identified outbreak, to 
establish possible transmission chains of this outbreak, thereby aiding in contact tracing and 







implementation of correct control measures. Another future study could focus on presenting 
the chronology of the primary X-family outbreak to identify if the outbreak is continuing 
despite the introduction of GeneXpert as the primary screening tool. 
 
We acknowledge the fact that, although spoligotyping is rapid and less expensive than other 
genotyping methods including IS6110-RFLP, it has less discriminatory power (49). In this 
study however, the predominant strain family identified was the X-family, a strain family that 
has less than 6 copies of IS6110 (50), rendering IS6110-RFLP also less discriminatory than 
when applied to other strain families with more copies of the insertion element. We also 
acknowledge that drug resistance conferring mutations are not ideal to use in generating 
phylogeny, as these mutations could have happened in parallel, and thereby indicating false 
transmission chains. However, the outbreak identified had a rare katG mutation with a 2 base 
pair change in the 315 codon which was also previously reported by our group (26) and also a 
specific pncA mutation. Mutations conferring PZA resistance in pncA is found throughout the 
gene, with no hotspot or preferential areas, suggesting that convergence will be minimal for 
this gene. 
 
In conclusion, we applied molecular epidemiological techniques in order a describe the DR-
TB population of the West Coast region of the Western Cape Province, South Africa – a 
region with high levels of tuberculosis disease including DR-TB, but with limited knowledge 
on the epidemiology of this region. We identified a predominant lineage responsible for the 
DR-TB epidemic – the X-family and showed the DR-TB epidemic is driven by transmission 
of MDR-TB strains, and acquisition of mutations leading to XDR-TB. 
 
This study emphasised the importance of using genotypic techniques in different regions to 
effectively implement surveillance studies in neglected areas. This will ultimately enable 
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 10XSSPE:    
13.7g Sodium Hydrogen Phopshate – 100mM 
105.19g Sodium Chloride-1.8M 
3.36g EDTA- 10mM 
Add distilled H2O to a volume of 1000ml 
pH = 7.40 
Store at room temperature  
 10% SDS: 
50g SDS 
Add dH2O to a volume of 500ml 
 0.5 EDTA:    
93g EDTA 
Add distilled H2O to a volume of 500ml                                                     
 
Working stocks 
 500ml 2xSSPE/0.1%SDS:   
100ml 10x SSPE 
5ml 10% SDS 
Add dH20 to a final volume of 500ml 
Store at room temperature 
 1000ml 2xSSPE/0.5%SDS:  
200ml 10x SSPE 
50ml 10% SDS 
Add distilled H20 to make a volume of 1000ml 
Store at room temperature 
 1000ml 1% SDS:   







100ml 10% SDS 
Add distilled H20 to make up a final volume of 1000ml 
 500ml 20mM EDTA:  
25ml 0.5M EDTA 
Add dH20 to make up a final volume of 500ml 
Store at 4°C 
 
PCR 
 Syto9 fluorescent dye (sensitive to light)   
5µl of Syto9  
Add 495µl of H2O and cover tube in foil  
Store at -20°C 
 dNTPs 
20µl of 100mM dATP 
20µl of 100mM dCTP 
20µl of 100mM dGTP 
20µl of 100mM dTTP 
Add 720µl of H2O  
Store at -20°C  
Primers  
 Primer stock: 
Add xµl per nmole of IDT primer 
Store at -20°C 
 Primer mix for Forward and reverse 
5µl of 1000µM of each primer stock 
Add 95µl of H2O to make a final volume of 100µl 
Store at -20°




































































































R R MDR 531TTG 315ACC 306ATA WT -15 C-T WT no result 
R 2320 X S R S S R R MDR 531TTG 315ACA 328TAT WT WT 94GGC 180GCC 




R R MDR 531TTG 315ACA 306GTG WT WT 91CCG 139ATG 
R 2401 X S S S S R R MDR 511CCG 315AAC WT WT WT WT WT 
R 2402 X S S S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 2409 X S S S S R R MDR 531TTG 315ACA WT WT WT WT WT 
R 2465 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 2591 X S S S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 




R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 




R R MDR 531TTG 315ACA 306GTG WT -15 C-T 90GTG 139ATG 




R R MDR 531TTG 315ACC 306ATA WT -15 C-T WT 154GGG 
R 2784 X S S S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 




R S Inh Mono WT 315ACC WT WT WT WT WT 




R S Inh Mono WT WT WT WT WT WT WT 
R 2871 X 
    
R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 2912 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT 89GGC 139ATG 




R S inh Mono 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 




R R MDR 531TTG 315ACC WT WT WT WT WT 
R 3040 X S S LV S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 




R R MDR 531TTG 315ACA WT WT WT WT WT 




R R MDR 526CTC 315ACA WT WT WT WT WT 
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R 3212 X S S S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 90GTG 139ATG 




R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 




R S Inh Mono 526CTC 315ACA 306ATA WT WT WT WT 
R 3241 X S S S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 3279 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 3315 X S S R S R R Pre XDR 531TTG 315ACA WT WT WT WT 139ATG 
R 3345 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 3355 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 3369 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 3385 X S S S S R R MDR 531TTG 315ACC WT WT WT WT WT 
R 3504 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 3505 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT WT 
R 3536 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 3542 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 




R R MDR 531ttg 315ACA 306GTG WT WT WT 139ATG 
R 3592 X S S S S R R MDR 531TTG 315ACA WT WT WT WT 139ATG 
R 3613 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 3632 X S S S S R R MDR 531TTG 315ACA WT WT WT WT WT 
R 3640 X S S R S R R Pre XDR 531TTG 315ACA 306GTG 1401A-G WT WT 139ATG 
R 3689 X S R S S R R MDR 531TTG 315ACA 306GTG WT WT 91CCG 139ATG 
R 3809 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 3816 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 3890 X S S S R R R Pre XDR 526GAC 315ACC WT WT WT WT 85CCG 
R 3929 X S S S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 90GTG WT 
R 3955 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 4017 X S S S 
 
R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
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R 4272 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 4280 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 4331 X R S S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 4518 X S S S S R R MDR 531TTG 315ACA 328TAT WT WT 94GGC 180GCC 
R 4582 X S S S S R R MDR 531TTG no result No result WT WT WT WT 
R 4591 X S S S S S R Rif Mono 531TTG WT WT WT WT WT WT 
R 4677 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 4835 X S S S S R R MDR 531TTG 315ACA 328TAT WT WT 94GGC 180GCC 
R 4845 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 4998 X R S S R R R Pre XDR WT 315ACA 306GTG WT WT 94GGC WT 
R 5022 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 5061 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 5286 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT 90GTG 139ATG 
R 5389 X S S S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 5496 X R S S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 5721 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 5738 X S S S S R R MDR 531TTG 315ACA 306ATA WT WT WT 139ATG 
R 5764 X S S S S R R MDR 526CTC 315ACA WT WT WT WT 143GTC 
R 5767 X S S S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 5775 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 5785 X S S S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 5847 X S S R R R R XDR 531TTG 315ACA 306GTG WT WT 91CCG 139ATG 
R 5985 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 5990 X S S S S S R Rif Mono 511CCG 315ACA WT WT WT WT WT 
R 6007 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 6115 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
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R 6175 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 6207 X S S S S R S Inh Mono WT WT WT WT -15 C-T WT WT 
R 6216 X S R R R R R XDR 531TTG 315ACA 306GTG 1401A-G WT 94GGC 139ATG 
R 6252 X S S S S R R MDR 531TTG 315ACC WT WT WT WT WT 
R 6278 X S S S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 6423 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 6477 X S R S R R R Pre XDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 6590 X S S S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 6630 X S S R R R R XDR 531TTG 315ACA 306GTG 1401A-G WT 90GTG 139ATG 
R 6661 X S S S S R R MDR 516TAC 315ACC 306ATA WT WT WT 68GGG 
R 6700 X S S R R R R XDR 531TTG 315ACA 306GTG 1401A-G WT 94GGC 139ATG 
R 6722 X S S S S R R MDR 531TTG 315ACC WT WT WT WT WT 
R 6880 X S S S S R S Inh Mono WT 315ACC WT WT WT WT WT 
R 6892 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT 91CCG 139ATG 
R 6956 X S S S S R R MDR 531TTG 315ACC 306GTG WT WT WT WT 
R 7067 X S S S S S R Rif Mono 511CCG WT WT WT WT WT WT 
R 7107 X S S S S R R MDR 531TTG 315ACA WT WT WT WT WT 
R 7152 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 7226 X S S S R R R Pre XDR 516GTC 315ACC WT WT WT WT WT 
R 7396 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 7479 X S S S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 7504 X S S S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 7718 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT 94GCC 139ATG 
R 7797 X S S S S R R MDR 531TTG 315ACA WT WT WT WT WT 
R 7963 X LV LV LV LV S R Rif Mono 511CCG WT WT WT WT WT WT 
R 8094 X S S S S R R MDR 531TTG 315ACA WT WT WT WT WT 
Stellenbosch University  https://scholar.sun.ac.za







R 8102 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 8536 X S S S S R R MDR 531TTG 315ACC WT WT WT WT WT 
R 8597 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 8868 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT WT WT 
R 8896 X S S S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 9099 X S S S S R R MDR 531TTG 315ACA WT WT WT WT WT 
R 9203 X S S S S R R MDR 531TTG 315ACA 306GTG WT WT 91CCG 139ATG 
R 9239 X S S S R R R Pre XDR 531TTG 315ACA 306ATT WT WT 94GGC WT 
R 9459 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT 94GCC 139ATG 
R 9548 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 9574 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 9576 X S ND S S R R MDR 531TTG 315ACC WT WT WT WT WT 
R 9660 X S ND S S ND ND Unclassified 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 9688 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 9861 X S ND S S R S Inh Mono 526CTC 315ACA WT WT WT WT WT 
R 9928 X S ND R S R R Pre XDR 526CTC 315ACA WT WT WT 90GTG WT 
R 10075 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT WT 
R 10173 X S ND S S R R MDR 531TTG 315ACA 328TAT WT WT 94GGC 180GCC 
R 10446 X S ND S S R R MDR 531TTG 315ACA WT WT WT WT 139ATG 
R 10661 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94AAC 139ATG 
R 10763 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 10764 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 10785 X S ND S S ND ND Unclassified 511CCG WT WT WT WT WT WT 
R 10821 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT WT 
R 10848 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 10857 X S ND S S R R MDR 531TTG 315ACA WT WT WT WT WT 
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R 10862 X S ND R S R R Pre XDR 531TTG 315ACA 306ATC 1401A-G WT WT WT 
R 11002 X S ND S S R R MDR 531TTG 315ACA WT WT WT WT WT 
R 11116 X S ND S S R R MDR 531TTG 315ACA WT WT WT WT WT 
R 11149 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 11193 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 90GTG 139ATG 
R 11268 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 11277 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT 143GTC 
R 11302 X S ND S R R R Pre XDR 531TTG 315ACC WT WT WT 94GGC 132AGT 
R 11358 X R ND S S R S Poly 526CTC 315ACA WT WT WT WT WT 
R 11440 X S ND S S R R MDR 531TTG WT 306GTG WT -15 C-T 94GGC 164CCG 
R 11501 X S ND R S R R Pre XDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 11572 X S ND R R R R XDR 531TTG 315ACA 306GTG 1401A-G WT 90GTG 139ATG 
R 11610 X S ND S R R R Pre XDR 531TTG no result 306GTG WT WT WT WT 
R 11635 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 11691 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 11724 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 11759 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 11781 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 11927 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 11989 X ND ND S S R R MDR WT 315ACC WT WT WT WT WT 
R 12007 X S ND S S S R Rif Mono 511CCG No result 306GTG WT WT WT WT 
R 12144 X S ND S S R R MDR 531TTG 315ACA 306GTG No result WT WT 139ATG 
R 12189 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 12193 X S ND R R R R XDR 531TTG 315ACA 306GTG 1401A-G WT 94GGC 139ATG 
R 12218 X S ND S S S R Rif Mono 511CCG 315ACA WT WT WT 94GGC WT 
R 12220 X S ND S S R R MDR 531TTG WT 306GTG WT WT WT 139ATG 
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R 12301 X S ND S R R R Pre XDR 531TTG 315ACA WT WT WT WT WT 
R 12350 X S ND S S S R Rif Mono 511CCG 315ACA WT WT WT 94GCC WT 
R 12374 X S ND S S R R MDR 531TTG WT 306GTG WT WT WT 139ATG 
R 12450 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 12533 X S ND R R R R XDR no result no result no result 1401A-G no result WT 139ATG 
R 12778 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 12780 X S ND S R R R Pre XDR 526CTC 315ACA WT WT WT WT 105GAC 
R 13097 X Cont ND Cont Cont S R Rif Mono 511CCG 315ACA WT WT WT 91CCG WT 
R 13458 X S ND S S R R MDR 531TTG WT 306GTG WT WT WT 139ATG 
R 13534 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 13658 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 13690 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 13734 X S ND S S R S Inh Mono WT 315ACA WT WT -15 C-T 94GCC 35CGG 
R 13778 X S ND S S S R Rif Mono 511CCG WT WT WT WT WT WT 
R 13928 X S ND S S R R MDR 531TTG WT 306GTG WT WT WT 139ATG 
R 14106 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GCC 139ATG 
R 14114 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GCC 139ATG 
R 14162 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 90GTG 139ATG 
R 14304 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 90GTG 139ATG 
R 14363 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT 90GTG 139ATG 
R 14382 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 14510 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 14748 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 14889 X S ND R S S R Poly 531TTG 315ACA WT 1401A-G WT WT WT 
R 14897 X S ND S S R R MDR 526CTC WT WT WT WT WT WT 
R 14913 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
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R 14973 X S ND S S R S Inh Mono WT 315ACA 306ATA WT -15 C-T WT WT 
R 15007 X S ND S S R R MDR 531TTG WT 306GTG WT WT WT 139ATG 
R 15070 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 15104 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 15158 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 15175 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 15340 X S ND S S R S Inh Mono WT 315ACC WT WT WT WT WT 
R 15414 X S ND S S R R MDR 531TTG 315ACA WT WT WT WT 139ATG 
R 15515 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 15667 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 15679 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT 143GTC 
R 15736 X S ND S R R R Pre XDR 531TTG 315ACC WT WT WT 94GGC 132AGT 
R 15740 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 15749 X S ND S S R R MDR 511CCG 315AGA WT WT WT WT WT 
R 15881 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 15952 X S ND S S R R MDR 531TTG 315ACA 306GTG no result WT WT 139ATG 
R 15982 X R ND S S R R MDR 531TTG 315ACA 306GTG no result WT WT 139ATG 
R 16010 X S ND S S S R Rif Mono 511CCG WT WT no result WT no result WT 
R 16166 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 16168 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 91CCG 139ATG 
R 16208 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 16244 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 16304 X R ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 16467 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 16690 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 16778 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
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R 16804 X R ND S S R R MDR 531TTG 315ACA 306GTG WT WT 90GTG 139ATG 
R 16835 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 16861 X S ND S S S R Rif Mono 511CCG WT WT 1402A WT WT WT 
R 16875 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 16946 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 17019 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 17024 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 17116 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 17168 X S ND S S R R MDR 531TTG 315ACC WT WT WT WT 132AGT 
R 17209 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT 94GCC 139ATG 
R 17267 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 17399 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 90GTG 139ATG 
R 17427 X S ND S S R R MDR 516GTC 315ACC WT WT WT WT WT 
R 17537 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 17584 X S ND S S S R Rif Mono 511CCG WT WT WT WT WT WT 
R 17592 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT WT WT 
R 17610 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT WT 
R 17614 X S ND S R R R Pre XDR 531TTG 315ACA 306GTG WT WT 94GGC 139ATG 
R 17632 X S ND S S S R Rif Mono 531TTG WT WT WT WT WT WT 
R 17699 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 18091 X S ND S R R R Pre XDR 533CCG 315ACA WT WT WT WT WT 
R 18107 X S ND S R R R Pre XDR 531TTG 315ACA WT WT WT WT 139ATG 
R 18128 X S ND S S R R MDR 531TTG 315ACC WT WT WT WT WT 
R 18252 X S ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 18593 X S ND S S R R MDR 526CTC 315ACA WT WT WT WT 62CTG 
R 18623 X S ND R S R R Pre XDR 531TTG 315ACA 306GTG 1401A-G WT WT 139ATG 
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R 18782 X R ND S S R R MDR 531TTG 315ACA 306GTG WT WT WT 139ATG 
R 18824 X S ND S S R R MDR 531TTG 315ACA no result WT WT WT no result 
R 18875 X S ND S S R R MDR 531TTG 315ACA no result WT WT WT no result 
R 18949 X S ND S S R R MDR no result no result no result no result no result no result no result 
R 18972 X S ND S S R R MDR 531TTG 315ACA no result WT WT WT no result 
R 18999 X S ND S S R R MDR 531TTG 315ACA no result WT WT 90GTG no result 
R 19106 X S ND S S R R MDR 531TTG 315ACA no result WT WT WT no result 
R 19118 X S ND S S S R Rif Mono 511CCG WT no result WT WT WT no result 
R 19242 X S ND S S R R MDR 531TTG 315ACA no result WT WT WT no result 
R 19248 X S ND S S R R MDR 531TTG 315ACA no result WT WT WT no result 
R 19269 X S ND S S S R Rif Mono 511CCG WT no result WT WT WT no result 
R 19409 X S ND S S R R MDR 531TTG 315ACA no result 1401A-G WT WT no result 
R 19529 X S ND R R R R XDR 531TTG 315ACA no result 1401A-G WT WT no result 
R 19881 X S ND S S R R MDR 531TTG 315ACA 306GTG no result WT WT 139ATG 
R 20008 X S ND S S R R MDR 531TTG 315ACA WT no result WT WT 139ATG 
R 20113 X S ND S S S R Rif Mono 511CCG WT WT no result WT WT WT 
R 20119 X S ND S S R S Inh Mono WT WT WT no result WT WT WT 
 
- DB-data base, R-resistant, S-susceptible, WT- wild type, ND- not done, LV-lost viability 
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